The Finnish diagnostics company is working to expand US and European sales of its ceramide lipid-based cardiovascular risk assessment assay, CERT.

The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.

While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.